Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $110.55

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the stock, MarketBeat reports. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $110.55.

A number of equities analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective for the company.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 22,929 shares of company stock valued at $2,634,220. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently modified their holdings of the stock. Redwood Financial Network Corp lifted its position in Gilead Sciences by 4.0% during the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC lifted its position in Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the last quarter. Nicolet Advisory Services LLC lifted its position in Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC lifted its position in Gilead Sciences by 1.7% during the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Finally, Perkins Coie Trust Co lifted its position in Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 2.8%

Shares of GILD opened at $109.11 on Wednesday. The stock has a market capitalization of $135.73 billion, a P/E ratio of 294.89, a PEG ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a fifty day simple moving average of $105.51 and a two-hundred day simple moving average of $100.02. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same period last year, the company posted ($1.32) EPS. The company’s quarterly revenue was down .3% compared to the same quarter last year. On average, research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.90%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.